Our current studies verified the hematopoietic function of JPYS by regulating EPO expression via hypoxia-inducible factor-1α in kidney cells, suggesting that JPYS could be employed as an alternative medicine for the treatment of CKD associated-anemia. Here, EPO is linked to chronic kidney disease.